Immunity against Mycobacterium tuberculosis during Active and Latent Tuberculosis
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Immunological Responses and Immune Defense Mechanisms".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 3294
Special Issue Editors
Interests: immune response; infection diseases; lung diseases; inflammation
Special Issue Information
Dear Colleagues,
Tuberculosis (TB) is the second leading infection killer after the current COVID-19 pandemic, and its causal agent is the bacilli Mycobacterium tuberculosis (Mtb). After exposure to Mtb, 5–10% of infected individuals develop active TB (ATB), and 90% develop a TB status called latent tuberculosis (LTB). The immune system of LTB patients controls the infection without eliminating Mtb.
TB patients display a chronic inflammation status. Mtb is an intracellular pathogen that mainly infects macrophages; however, it currently is well known that Mtb manipulates the host’s immune response to survive during the host’s life. Thus, the study of the immune response during TB is fundamental to the development of new therapies, vaccines, and diagnoses.
Potential topics include but are not limited to the following:
- Role of Monocytes/Macrophages during the pathogenic mycobacteria infection;
- Immune responses during latent tuberculosis;
- Immune response during active tuberculosis;
- Cell death during the pathogenic mycobacteria infection;
- Advances in diagnosis development to latent and active tuberculosis.
For this Special Issue, we cordially invite you to contribute with an article that provides new knowledge regarding the role of the immune response against Mtb. Research articles, reviews, case reports, and meta-analyses are welcome to be considered for publication after rigorous peer review.
Dr. Leslie Chavez-Galan
Dr. Rogelio Hernández-Pando
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- monocytes/macrophages
- inflammation
- immune response
- tuberculosis
- pathogenesis
- diagnosis
